Eli Lilly and Company $LLY Shares Sold by InvesTrust

Key Points

• InvesTrust reduced its stake in Eli Lilly and Company by 39.8% during the second quarter, selling 4,313 shares and retaining ownership of 6,528 shares, valued at approximately $5,089,000.
• Several institutional investors, including Brighton Jones LLC and Breed’s Hill Capital LLC, increased their stakes in Eli Lilly, highlighting strong institutional interest in the stock, which is predominantly held by institutional investors at 82.53%.
• Eli Lilly reported a $6.31 EPS for the last quarter, exceeding analysts' expectations, along with a significant year-over-year revenue increase of 37.6%, setting positive guidance for FY 2025.

InvesTrust decreased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 39.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,528 shares of the company's stock after selling 4,313 shares during the period. Eli Lilly and Company comprises 2.0% of InvesTrust's investment portfolio, making the stock its 15th biggest position. InvesTrust's holdings in Eli Lilly and Company were worth $5,089,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. PNC Financial Services Group Inc. increased its holdings in shares of Eli Lilly and Company by 97.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares during the last quarter. GAMMA Investing LLC grew its stake in Eli Lilly and Company by 103,831.6% during the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock worth $12,278,292,000 after buying an additional 14,852,076 shares during the last quarter. Nuveen LLC purchased a new position in Eli Lilly and Company during the 1st quarter worth approximately $4,613,912,000. Vanguard Group Inc. grew its stake in Eli Lilly and Company by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock worth $65,432,218,000 after buying an additional 4,975,395 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Eli Lilly and Company by 15.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,084,880 shares of the company's stock worth $5,469,527,000 after acquiring an additional 969,376 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Buying and Selling

In related news, CEO David A. Ricks purchased 1,632 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the acquisition, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jamere Jackson purchased 200 shares of the business's stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 4,514 shares of company stock valued at $2,894,841. Company insiders own 0.14% of the company's stock.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent research reports. HSBC raised Eli Lilly and Company from a "reduce" rating to a "hold" rating and increased their price objective for the stock from $675.00 to $700.00 in a research report on Wednesday, August 27th. Leerink Partners reissued a "market perform" rating and issued a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. Leerink Partnrs cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. Finally, Erste Group Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus price target of $941.35.

Eli Lilly and Company Price Performance

LLY stock traded down $1.38 during midday trading on Friday, hitting $754.90. 2,195,977 shares of the stock were exchanged, compared to its average volume of 3,436,359. The stock's 50-day moving average price is $741.03 and its 200-day moving average price is $775.51. The stock has a market cap of $714.48 billion, a price-to-earnings ratio of 49.34, a PEG ratio of 1.05 and a beta of 0.47. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $942.35. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the previous year, the firm posted $3.92 earnings per share. The business's revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend was Friday, August 15th. Eli Lilly and Company's payout ratio is 39.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.